Description
Inclisiran is used to treat people with high cholesterol, atherosclerotic cardiovascular disease (ASCVD), and familial heterozygous hypercholesterolemia (HeFH). It can be used along with diet changes and other treatments.
Sybrava (Inclisiran) Injection, Initial U.S. Approval: 2022
References
- Novartis Pharmaceuticals Corporation , US Food and Drug Administration, [ Revised on July 2023] [ Accessed on 05-03-2024 ], https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214012s009lbl.pdf
- Novartis Pharmaceuticals UK Ltd. Electronic medicines compendium (emc), [ Revised on November 2022] [ Accessed on 05-03-2024], https://www.medicines.org.uk/emc/files/pil.12039.pdf
- Leqvio, Novartis Pharmaceuticals Ltd, https://www.leqvio.com/
Note:
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient. Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.